This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for INmune Bio, Inc. (INMB) points to a 98.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can INmune Bio, Inc. (INMB) Climb 105% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 104.7% upside potential for INmune Bio, Inc. (INMB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
New Analysts Initiate Coverage: 5 Stocks for Higher Returns
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Malibu (MBUU), Cantaloupe (CTLP), INmune (INMB), Swedish Match (SWMAY) and GATX.
INmune Bio (INMB) Down on Clinical Hold for Alzheimer's Study
by Zacks Equity Research
The FDA places clinical hold on INmune Bio's (INMB) IND application to begin a phase II study on the investigational TNF inhibitor, XPro1595, for Alzheimer's disease.
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
by Zacks Equity Research
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate
by Zacks Equity Research
INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.
Biogen (BIIB) Seeks Approval for Another Alzheimer's Candidate
by Zacks Equity Research
Biogen (BIIB) and partner Eisai start rolling submission of a regulatory filing seeking approval for lecanemab (BAN2401) as a potential approval for early Alzheimer's disease.
Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and BioMarin (BMRN), among others, have been in focus in the biotech industry over the past week.
INmune (INMB) Announces Positive Data for its AD Candidate
by Zacks Equity Research
INmune Bio (INMB) announces positive data for its AD candidate, XPro, from an early stage study. Shares are up in pre-market.
6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day
by Kinjel Shah
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.